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Available online 17 February 2016Background: IgA nephropathy (IgAN) and Henoch-Schönlein purpura nephritis (HSPN) are glomerular diseases
that share a common and central pathogenic mechanism. The formation of immune complexes containing
IgA1, myeloid IgA Fc alpha receptor (FcαRI/CD89) and transglutaminase-2 (TG2) is observed in both conditions.
Therefore, urinary CD89 and TG2 could be potential biomarkers to identify active IgAN/HSPN.
Methods: In this multicenter study, 160 patients with IgAN or HSPN were enrolled. Urinary concentrations of
CD89 and TG2, as well as some other biochemical parameters, were measured.
Results:Urinary CD89 andTG2were lower in patientswith active IgAN/HSPN compared to IgAN/HSPN patients in
complete remission (P b 0.001). The CD89xTG2 formula had a high ability to discriminate active from inactive
IgAN/HSPN in both situations: CD89xTG2/proteinuria ratio (AUC: 0.84, P b 0.001, sensitivity: 76%, speciﬁcity:
74%) andCD89xTG2/urinary creatinine ratio (AUC: 0.82, P b 0.001, sensitivity: 75%, speciﬁcity: 74%). Signiﬁcant
correlations between urinary CD89 and TG2 (r = 0.711, P b 0.001), proteinuria and urinary CD89 (r =−0.585,
P b 0.001), and proteinuria and urinary TG2 (r =−0.620, P b 0.001) were observed.
Conclusions:Determination of CD89 and TG2 in urine samples can be useful to identify patients with active IgAN/
HSPN.




Myeloid IgA Fc alpha receptor
Transglutaminase-21. Introduction
IgA nephropathy (IgAN) is the most prevalent form of chronic glo-
merulonephritis in the world with an estimated frequency of at least
2.5 cases per year per 100,000 adults [1]. The exact cause of primary
IgAN is still unknown, but its onset is commonly associated with
upper respiratory tract infections and episodes of macroscopic hematu-
ria [2,3]. Henoch-Schönlein purpura (HSP) is the most frequent form of
vasculitis in children and about 40% of children with HSP develop ne-
phritis (HSPN) [4,5]. Although in the majority of cases a benign and
self-limiting course is observed, some patientswithHSPN can potential-
ly progress to end-stage renal disease (ESRD) [4]. Actually, up to 30% ofChemistry, Ghent University
e).
pen access article under the CC BY-NIgAN patients progress to ESRD by 20 years, and many of these patients
need for renal replacement treatment [6,7].
The clinical, genetic and immunologic characteristics of IgAN and
HSPN are closely linked, and HSPN can be considered as the systemic
form of IgAN [4,8,9]. IgAN and HSPN share a common and central path-
ogenic mechanism associated with an aberrant O-linked glycosylation
in the hinge region of IgA1 molecules [2,4,5,10,11]. The recognition of
this IgA1 hinge region neoepitope by naturally occurring IgA1 or IgG an-
tibodies leads to generation of immune complexes in the circulation and
to deposition of these nephrotoxic immune complexes in the glomerulus
[12]. The formation of undergalactosylated, large-molecular-mass IgA1-
IgG containing immune complexes forms a part of the not yet fully eluci-
dated pathogenesis of IgAN [13]. However, some key molecules have
been identiﬁed, which contribute to the formation of the immune com-
plexes: myeloid IgA Fc alpha receptor (FcαRI/CD89), transglutaminase-
2 (TG2) and transferrin receptor (TfR/CD71) [1,13–17].C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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mainly on the surface of myeloid cells that binds both IgA1 and IgA2
with a similar afﬁnity [18,19]. TG2 (EC 2.3.2.13), the most ubiquitously
expressed member of the transglutaminase family, has been proposed
to be responsible for a pathogenic ampliﬁcation loop, facilitating IgA1-
CD89 deposition and mesangial cell activation in IgAN [16]. Additional-
ly, it has been suggested that the aberrant glycosylated IgA1 stimulates
the expression ofmesangial CD71 andmediatesmesangial deposition of
nephritogenic IgA1-immune complexes [20–22]. A new and sensitive
latex-enhanced nephelometric assay for measurement of urinary
CD71 has recently been developed by our team. In a previous study,
we have demonstrated that urinary CD71 concentrations were higher
in patients with active IgAN/HSPN in comparison with patients with
other types of glomerulopathy [13].
The measurement of novel urinary biomarkers might be a tool to
provide meaningful information for the diagnosis of IgAN/HSPN. An
early diagnosis is crucial to prevent the progression of these diseases
to ESRD [13,23]. In addition, no attempts have been made to determine
the urinary concentration of CD89 and TG2 in IgAN/HSPN patients.
Therefore, in the present study we have investigated the potential use
of urinary CD89 and TG2 as new biomarkers in IgAN/HSPN.
2. Subjects and methods
2.1. Patients
A total of 160 Caucasian patients with a biopsy proven IgAN or HSPN
(95males, 65 females, mean age± SD: 36.8± 19.8 years)were consec-
utively recruited between November 2012 and February 2015 in this
multicenter study [Department of Nephrology at the Ghent University
Hospital (Gent, Belgium), Department of Nephrology and Transplanta-
tion Medicine at the Wroclaw Medical University (Wroclaw, Poland),
Department of TransplantationMedicine and Nephrology, Medical Uni-
versity of Warsaw (Warsaw, Poland) and Department of Emergency
and Organ Transplantation, Section of Nephrology at University of Bari
“AldoMoro” (Bari, Italy)]. Renal biopsies of IgANwere scored accord-
ing to the Oxford MEST scoring system by pathologists experienced
in the classiﬁcation. The MEST score was deﬁned as follows: M0/M1
as a mesangial score ≤ or N 0.5, or ≤ or N 50% of glomeruli with ≥ 4
mesangial cells permesangial area, E0/E1 as the presence or absence
of endocapillary hypercellularity, S0/S1 as the presence or absence
of segmental sclerosis or tuft adhesions, and T0/T1/T2 as the degree
of tubular atrophy or interstitial ﬁbrosis (b 25%, 25–50%, N 50%, re-
spectively) [24]. The biopsy ﬁndings of HSPNwere graded according
to the classiﬁcation developed by the International Study of Kidney
Disease in Children (ISKDC) [25]: (I) minimal glomerular abnormal-
ities, (II)mesangial proliferation (MP), (III)MPwith b 50% crescents,
(IV), MP with 50–75% crescents, (V) MP with N 75% crescents, and
(VI) membranoproliferative-like lesions.
Reviewing literature, the proposed remission criteria of IgAN/
HSPN vary depending on the clinical studies. Therefore, a uniform
assessment of treatment outcomes and a standardization of expla-
nations of the condition is difﬁcult. We opted to classify the disease
status of IgAN/HSPNpatients based on the proteinuria cutoff criteria
[26]. A complete remission was deﬁned as a proteinuria level
ofb 0.03 g/mmol creatinine, a partial remissionwas deﬁned as a pro-
teinuria level of 0.03 to 0.11 g/mmol creatinine and an active disease
status correspondedwith a proteinuria level of N 0.11 g/mmol creat-
inine. This studywas approved by the local Ethics ReviewBoard accord-
ing to the Declaration of Helsinki and all patients signed an informed
consent.
2.2. Routine biochemistry analyses
Urine samples were collected at time of diagnosis or during the
follow up period and sent to the laboratory of the Ghent Universityhospital, where they were stored at− 80 °C, awaiting further analy-
ses. Stability tests showed no signiﬁcant inﬂuence of the storage
procedure on the measured parameters. Spot urine samples were
centrifuged at 3000×g for 10 min before testing. The total urinary pro-
tein concentration was assayed using a pyrogallol red-based colorimet-
ric assay [27] on a Cobas 8000®modular analyzer (Roche Diagnostics®,
Mannheim, Germany), and serum creatinine levels weremeasured by a
rate-blanked compensated Jaffe method on the same analyzer. The
urinary IgA concentration was measured on a BN II nephelometer
(Siemens®, Marburg, Germany) according to the manufacturer's in-
structions. The intra-assay coefﬁcient of variation (CV) and inter-assay
CV were b5%. The estimated glomerular ﬁltration rate (eGFR) of each
participant wasmeasuredwith the Chronic Kidney Disease Epidemiolo-
gy Collaboration (CKD-EPI) equation, which includes age, sex, race and
serum creatinine levels [28].
2.3. Urinary soluble transferrin receptor (sTfR, CD71) assay
The spot urine samples were concentrated tenfold by ultraﬁltration
on a polyethersulfonemembranewith a 7.5 kDa cutoff (Vivapore®, Sar-
torius Stedim Lab, Gloucestershire, UK). The urinary CD71 concentra-
tion was assayed in the concentrate by use of a newly developed
latex-enhanced immunonephelometric assay on a BN II nephelometer
(Siemens®, Marburg, Germany), as previously described in detail and
validated by our research team [13]. The intra-assay coefﬁcient of vari-
ation (CV) was 3.0% and inter-assay CV was 3.1%.
2.4. Urinary Fc fragment of IgA receptor (FcaR, CD89) assay
The urinary CD89 concentration was assayed in spot urine samples
by an enzyme-linked immunosorbent assay (ELISA)with a human anti-
body speciﬁc to CD89 (Cloud-CloneCorp®,Houston, TX, USA) according
to the manufacturers' instructions. Brieﬂy, 100 μL of standards or urine
was added to the wells and incubated for 120 min at 37 °C. The liquid
of each well was removed and 100 μL of biotin-conjugated antibody
speciﬁc for the human Fc fragment of the IgA receptor (primary an-
tibody)was added. After 1 h of incubation, the liquid was removed and
each well was washed three times with 350 μL of wash solution. 100 μL
of avidin conjugated to horseradish peroxidase (HRP) was added to
each microplate well and incubated for 30 min at 37 °C. Free compo-
nents were washed ﬁve times with 350 μL of wash solution and 90 μL
of substrate solutionwas added to eachwell. After 15min of incubation,
50 μL of stop solutionwas added to eachwell. The optical density (O.D.)
was immediatelymeasured at 450 nmby theuse of the automated Zenit
UP (A. Menarini Diagnostics®, Florence, Italy) system. The urinary con-
centrations of CD89 were calculated after comparing the O.D. of the
samples with the standard curve in the Microplate Manager® version
4.0 software (Bio-Rad Laboratories®, Hercules, CA, USA). The detection
range of this assay was 0.781–50 ng/mL and its sensitivity was
0.35 ng/mL. Intra-assay CV was b10% and inter-assay CV was b12%.
2.5. Urinary transglutaminase 2 (TG2) assay
The urinary TG2 concentrationwas assayed in spot urine samples by
an ELISA with a human antibody speciﬁc to TG2 (Elabscience®,Wuhan,
China) according to the manufacturers' instructions. Brieﬂy, 100 μL of
standards or urine was added to the wells and incubated for 90 min at
37 °C. The liquid of each well was removed and 100 μL of biotinylated
detection antibody speciﬁc for human TG2 (primary antibody) was
added. After 1 h of incubation, the liquid was removed and each well
was washed three times with 350 μL of wash solution. 100 μL of HRP
conjugate was added to each well and incubated for 30 min at 37 °C.
Free components were washed ﬁve times with 350 μL of wash solution
and 90 μL of substrate solution was added to each well. After 15 min of
incubation, 50 μL of stop solution was added to each well. The O.D. was
immediately measured at 450 nm by use of the automated Zenit UP (A.
Fig. 1. Comparison of (A) urinary CD89 (ng/mg protein), (B) urinary transglutaminase-2
(TG2) (ng/mg protein) and (C) urinary CD71 (ng/mg protein) in patients with IgA
nephropathy or Henoch-Schönlein purpura nephritis (IgAN/HSPN) in complete
remission (CR), partial remission (PR) or active disease. Results are expressed as
medians and interquartile ranges.
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tions of TG2 were calculated after comparing the O.D. of the samples
with the standard curve in the Microplate Manager® version 4.0 soft-
ware (Bio-Rad Laboratories®, Hercules, CA, USA). The detection range
of this assay was 0.156–10 ng/mL and its sensitivity was 0.094 ng/mL.
The intra-assay and inter-assay CV were b10%.
2.6. Statistical analysis
The distribution of variables was tested using the Kolmogorov–
Smirnov test. Continuous variableswere reported asmean±standardde-
viation (SD)or 95% conﬁdence interval (CI) ormedianwith interquartile
ranges (IQR). Categorical data were summarized as percentages and a
comparison between groups was performed with the χ2 test. Statistical
differences between groups were evaluated by one-way analysis of vari-
ance (ANOVA) followed by the Tukey's multiple comparison test or the
Kruskal-Wallis test followed by the Dunn'smultiple comparison test. Cor-
relation analysis was performed with the nonparametric Spearman rank
test. Receiver operating characteristics (ROC) curve was performed to
quantify the overall ability of biomarkers to discriminate active frominac-
tive IgAN/HSPN. Contingency tables were evaluated by Fisher's exact test.
All hypothesis testswere performed as 2-sided at the 5% signiﬁcance level.
A P value of b0.05was considered to be statistically signiﬁcant. Data were
analyzed using GraphPad Prism 4.00 for Windows (GraphPad Software,
San Diego, CA) and Statistica 6.0 (StatSoft Inc., Tulsa, OK).
3. Results
Themean follow timebetweendiagnosis of IgANofHSPN and the
analysis of the investigated biomarkers in the present study was
52months [95% CI: 38–66months]. 46% of the patients were includ-
ed in the study at the time of diagnosis, whereas 54% of the samples
were collected during the follow up period. At the time of inclusion,
38% of the patients were treated with angiotensin converting
enzyme inhibitors or angiotensin II receptor blockers, 16%with cor-
ticosteroids, 10% with another immunosuppresive drug (mycophe-
nolate mofetil, cyclosporin or azathioprine) and 4% with ﬁsh oil/
omega-3 fatty acids. An overview of the baseline characteristics and
biochemical parameters of the study participants is summarized in
Table 1. The levels of proteinuria and the urinary IgA concentrations
were higher in patients with active IgAN/HSPN compared with those
in complete or partial remission. A signiﬁcant decrease in kidney func-
tion was observed in patients with active IgAN/HSPN compared with
the group in complete or partial remission.
The urinary CD89 concentration was statistically lower in patients
with active IgAN/HSPN compared to IgAN/HSPN patients in complete
or partial remission (P b 0.001) (Fig. 1A). In addition, the urinary TG2
concentration was lower in patients with active IgAN/HSPN than
IgAN/HSPN patients in complete remission (P b 0.001) (Fig. 1B).No sig-
niﬁcant difference in the urinary CD71 concentrationwas found be-
tween the different stages of IgAN/HSPN (Fig. 1C). Patientswith active
IgAN/HSPN had signiﬁcantly higher IgA/CD89, IgA/TG2 and IgA/
CD89xTG2 ratios than IgAN/HSPN patients in complete or partialTable 1
Overview of baseline characteristics and parameters of the study patients.
IgAN/HSPN in complete remission
(deﬁned as proteinuria b0.03 g/mmol creatinine)
IgAN/HSPN in partial remission
(deﬁned as proteinuria 0.03 to
0.11 g/mmol creatinine)
Active IgAN/HSPN
(deﬁned as proteinuria N0.11 g/mmol creatinine)
P-value
n 67 51 42 -
Age (years) 37.9 ± 22.9 32.6 ± 17.3 40.3 ± 16.5 0.164
Male (%) 59.7 52.9 66.7 0.406
eGFR (mL/min/1.73m2) 84.2 ± 33.4 76.8 ± 30.1 59.0 ± 33.9 0.002
Urinary IgA
(mg/mmol creatinine)
0.14 (0.08–0.25) 0.44 (0.28–0.72) 2.56 (1.37–3.79) b0.001
Results are expressed as %, mean ± SD or median (IQR). Abbreviations: IgAN, IgA nephropathy; HSPN, Henoch-Schönlein purpura nephritis; eGFR, estimated glomerular ﬁltration rate.
Fig. 2. Comparison of (A) urinary IgA/CD89 ratio, (B) urinary IgA/TG2 ratio, (C) urinary IgA/CD89xTG2 ratio and (D) urinary CD89xTG2 in patients with IgA nephropathy or Henoch-
Schönlein purpura nephritis (IgAN/HSPN) in complete remission (CR), partial remission (PR) or active disease. Results are expressed as medians and interquartile ranges.
82 R.N. Moresco et al. / BBA Clinical 5 (2016) 79–84remission (Figs. 2A, B and C). In contrast, CD89xTG2 values were lower
in patients with active IgAN/HSPN compared with IgAN/HSPN patients
in complete or partial remission (P b 0.001 and P b 0.01, respectively)
(Fig. 2D).
ROC curve analysis was employed to quantify the ability of the uri-
nary biomarkers to identify active IgAN/HSPN. Overall AUCs of CD89,
TG2, CD89xTG2, IgA/CD89, IgA/TG2 and IgA/CD89xTG2 were 0.82,
0.81, 0.84, 0.80, 0.79 and 0.86, respectively, and all of these AUCs were
statically signiﬁcant (P b 0.001) (Table 2). Urinary CD71 (ng/mg pro-
tein) was not able to discriminate active from inactive IgAN/HSPN
(AUC: 0.57, P = 0.240). However, the urinary CD71/creatinine ratio
(ng/mg creatinine) was able to identify active IgAN/HSPN (AUC: 0.69,
P b 0.01). Additionally, we investigated if the corrections by urinary
creatinine affected the diagnostic ability of the other biomarkers. The
overall AUCs of the CD89/urinary creatinine ratio, the TG2/urinary
creatinine ratio, the CD89xTG2/urinary creatinine ratio, the IgA/Table 2
Characteristics of urinary biomarkers for assessment of active IgA nephropathy/Henoch-
Schönlein purpura nephritis (IgAN/HSPN).




CD89 0.82 0.74–0.90 b0.001 50 81 72
TG2 0.81 0.73–0.89 b0.001 7.2 78 72
CD89xTG2 0.84 0.76–0.92 b0.001 380 76 74
IgA/CD89 0.80 0.72–0.89 b0.001 163 71 76
IgA/TG2 0.79 0.69–0.88 b0.001 1257 76 74
IgA/CD89xTG2 0.86 0.78–0.93 b0.001 30 84 76
IgA, immunoglobulin A; CD89, myeloid IgA Fc alpha receptor; TG2, transglutaminase-2.CD89/urinary creatinine ratio, the IgA/TG2/urinary creatinine
ratio and the IgA/CD89xTG2/urinary creatinine ratio were 0.78
(P b 0.001), 0.78 (P b 0.001), 0.82 (P b 0.001), 0.80 (P b 0.001), 0.79
(P b 0.001) and 0.54 (P = 0.549), respectively. The IgA/CD89xTG2
ratio had a slightly higher ability to discriminate active from inactive
IgAN/HSPN (sensitivity: 84%, speciﬁcity: 76%) in comparison with the
other studied biomarkers. However, after the correction by urinary cre-
atinine, the IgA/CD89xTG2 ratio was not able to discriminate active
from inactive IgAN/HSPN (AUC: 0.54, P = 0.549). In addition, the
CD89xTG2 demonstrated a high ability to distinguish active IgAN/
HSPN in both situations: CD89xTG2/proteinuria ratio (AUC: 0.84,
P b 0.001, sensitivity: 76%, speciﬁcity: 74%) and CD89xTG2/urinary cre-
atinine ratio (AUC: 0.82, P b 0.001, sensitivity: 75%, speciﬁcity: 74%).
A signiﬁcant correlation between urinary CD89 and urinary TG2
(r = 0.711, P b 0.001) was observed in the study patients. Further-
more, signiﬁcant correlations between proteinuria and urinary
CD89 (r = −0.585, P b 0.001), and proteinuria and urinary TG2
(r =−0.620, P b 0.001) were observed, but not for proteinuria and
urinary CD71 (r = 0.047, P=0.526). Fig. 3 shows the logarithmic re-
lationships among proteinuria (g/L), urinary CD71 (ng/mg protein),
urinary CD89 (ng/mg protein) and urinary TG2 (ng/mg protein) in
the study patients.
4. Discussion
The present study establishes the value of urinary CD89 and TG2 as
new and non-invasive biomarkers useful for identifying of active
IgAN/HSPN. Although previous studies have indicated the role of CD89
and TG2 in the pathogenesis of IgAN [1,14–16], this study reports for
Fig. 3. Logarithmic relationships among proteinuria (g/L), urinary CD71 (ng/mg protein),
urinary CD89 (ng/mg protein) and urinary TG2 (ng/mg protein) in the study patients.
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with IgAN/HSPN. Actually, anatomopathological analysis of renal biop-
sies is required for the deﬁnitive diagnosis of IgAN or HSPN [1,29–32].
However, a renal biopsy is frequently not performed for different rea-
sons and has some limitations in the assessment of disease activity
[30,31]. For this reason, there is an urgent need for reliable noninvasive
biomarkers that might be applicable for detecting and monitoring of
IgAN/HSPN.
The major ﬁndings of the present study are that urinary CD89 and
urinary TG2 were decreased in patients with active IgAN/HSPN com-
pared to subjects with a partial or complete remission of IgAN/HSPN.
In addition, both urinary biomarkers have the ability to discriminate ac-
tive from inactive IgAN/HSPN. It is well established that the aberrant
glycosylated IgA1 in IgAN/HSPN leads to the release of soluble IgA re-
ceptors as CD89 and to the formation and ampliﬁcation of circulating
immune complexes [33,34]. The soluble CD89-IgA complex deposition
induces an inﬂux of mononuclear cells into the glomerular and intersti-
tial regions and initiates an inﬂammatory reaction [33]. As a conse-
quence, there is a decrease of urinary excretion of CD89 since this
molecule appears to remain in the kidney during the active phase of
IgAN/HSNP. However, some studies have indicated that human
mesangial cells do not express CD89 to a signiﬁcant extent [35] and
that IgA-CD89 complexes are not speciﬁc for primary IgAN [36]. In addi-
tion, IgA-CD89 complexes were found in the serum of healthy individ-
uals [18] at equal amounts of IgA-CD89 complexes present in IgAN
patients [36]. Although there is some conﬂicting evidence regarding
the CD89 and CD89-IgA complexes in patients with IgAN/HSPN, the
few conducted studies have evaluated these molecules especially in
serum samples. Until now, there are no data in the literature regarding
the urinary CD89 concentration in patients with IgAN/HSPN. We have
demonstrated in this study that the urinary CD89 concentrations were
signiﬁcantly reduced in patients with active IgAN/HSPN. Therefore,
this ﬁnding opens a new perspective for the measurement of CD89 in
urine samples as a way to monitor and diagnose IgAN/HSPN. It can
help to understand the pathophysiological mechanisms related to the
formation and deposition of the immune complexes as CD89 plays a
crucial role in the clearance of IgA-complexes [37].
Our research also demonstrated that the urinary TG2 concentration
was lower in patients with active IgAN/HSPN compared to non-active
IgAN/HSPN patients. During the active phase of the disease, there is a
stabilization of large multimolecular complexes containing CD89, TG2,
CD71 and IgA1 on the mesangial cell surface, which induce chronic
stimulation of the cells with release of pro-inﬂammatory mediators
leading to renal dysfunction [16]. With the deposition and stabilizationof these multimolecular complexes in the kidney, there is a decrease in
the renal excretion of CD89 and TG2. Additionally, TG2 stabilized in the
mesangium can contribute to the development of renal ﬁbrosis [38,39]
and vascular calciﬁcation [40], leading to a decline in renal function. Fur-
thermore, patients with active IgAN/HSPN had signiﬁcantly higher IgA/
CD89, IgA/TG2 and IgA/CD89xTG2 ratios comparedwith IgAN/HSPN pa-
tients in complete or partial remission. In contrast, CD89xTG2 values
were lower in patients with active IgAN/HSPN compared with IgAN/
HSPN patients in complete or partial remission. The CD89xTG2 had a
high ability to discriminate active from inactive IgAN/HSPN, as demon-
strated in the CD89xTG2/proteinuria ratio and in the CD89xTG2/uri-
nary creatinine ratio. These results demonstrate that differences
becomemore signiﬁcant and the performance to discriminate the active
phase of the disease is slightly higher when mathematical formulas in-
volving both CD89 and TG2 are evaluated.
Moreover, a signiﬁcant positive correlation between urinary CD89
and urinary TG2 was observed. Both molecules are present in immune
complexes, which are stabilized on the mesangial cell surface during
the active IgAN/HSPN [16]. Signiﬁcant negative correlations between
proteinuria, urinary CD89 and urinary TG2 were observed, but not for
urinary CD71. The urinary CD71/creatinine ratios were able to identify
the active IgAN/HSPN. Aberrant glycosylated IgA1 promotes an in-
creased expression of the mesangial CD71 and mediates mesangial de-
position of nephritogenic IgA1-immune complexes [20–22] and the
evaluation of urinary CD71 can add information about the course of
this disease [13].
Finally, some interesting logarithmic relationships among protein-
uria, urinary CD89, and urinary TG2 were observed in the present
study. As illustrated in Fig. 3, a signiﬁcant reduction in the urinary con-
centrations of CD89 and TG2 in patients with IgAN/HSPNwas observed,
even in the presence of a mild proteinuria. The reduction of the bio-
marker according to the increase of proteinuria is more prominent for
CD89, which suggests that CD89 might decrease earlier than TG2 in
the urine of patients with IgAN/HSPN.
A limitation of the study is that there is a lack of standardization of
the measurement of CD71, CD89 and TG2, which limits the diagnostic
power of the investigated parameters, because it makes it difﬁcult to
compare the results among different studies. In addition, as the analysis
of the biomarkers was also performed on urine samples during the fol-
low period of the IgAN/HSPN patients, no correlation analysis with the
results of the biopsies could be performed.
In conclusion, our results showed that urinary CD89 and TG2 were
decreased in patients with active IgAN/HSPN, and the measurement of
these newbiomarkers in urine samples can beuseful to identify patients
with the active disease. However, further longitudinal studies are
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